Bar Harbor Wealth Management Raises Holdings in AbbVie Inc. $ABBV

Bar Harbor Wealth Management boosted its stake in AbbVie Inc. (NYSE:ABBV) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,092 shares of the company’s stock after purchasing an additional 3,690 shares during the period. AbbVie makes up about 1.2% of Bar Harbor Wealth Management’s investment portfolio, making the stock its 22nd biggest holding. Bar Harbor Wealth Management’s holdings in AbbVie were worth $21,271,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie during the second quarter valued at about $26,000. Chelsea Counsel Co. acquired a new stake in shares of AbbVie during the third quarter valued at about $26,000. Westend Capital Management LLC acquired a new stake in shares of AbbVie during the fourth quarter valued at about $29,000. Texas Capital Bancshares Inc TX acquired a new stake in shares of AbbVie during the third quarter valued at about $31,000. Finally, Caitlin John LLC acquired a new stake in shares of AbbVie during the third quarter valued at about $33,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Performance

NYSE ABBV opened at $208.22 on Friday. AbbVie Inc. has a twelve month low of $168.54 and a twelve month high of $244.81. The stock has a market cap of $368.16 billion, a price-to-earnings ratio of 88.23, a PEG ratio of 0.76 and a beta of 0.38. The firm’s 50 day moving average price is $220.35 and its two-hundred day moving average price is $224.01.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the previous year, the company posted $2.16 EPS. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.

Insider Buying and Selling at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Guggenheim raised its price target on ABBV to $249 and reiterated a Buy, signaling upside from analysts who still favor the name. Guggenheim Reiterates Buy Rating on Abbvie (ABBV)
• Positive Sentiment: Short interest fell ~19.9% in March (to ~20.1M shares), reducing short-pressure and the risk of further downside driven by short covering dynamics; days-to-cover near 2.5.
• Positive Sentiment: Analysts and features continue to highlight AbbVie’s successful product transition: Skyrizi and Rinvoq are driving strong immunology growth that offsets Humira erosion — supportive for medium-term revenue and dividend durability. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
• Neutral Sentiment: AbbVie has launched legal action challenging the federal 340B patient definition — this could protect pricing/discount exposure if successful but outcome and timing are uncertain. AbbVie challenges ‘outdated’ 340B drug discount program guidance in new lawsuit
• Neutral Sentiment: Dividend-focused coverage continues to list ABBV among reliable dividend names (Dividend Aristocrat), reinforcing long-term income investor interest but not an immediate price catalyst. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Negative Sentiment: AbbVie lowered its Q1 and FY 2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), which is the primary near-term negative catalyst—investors often sell when guidance trails consensus.
• Negative Sentiment: Cantor Fitzgerald trimmed its target to $240 and warned that the upcoming Q1 season may not materially re‑energize sentiment, reinforcing caution after AbbVie’s guidance revision. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead
• Negative Sentiment: RBC said first-quarter results are likely to land inside AbbVie’s guidance and may not lift investor sentiment — a signal that the report could be bland relative to expectations. AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says
• Negative Sentiment: Broader health-care sector weakness late Friday weighed on ABBV alongside idiosyncratic negatives, amplifying downward pressure. Sector Update: Health Care Stocks Fall Late Afternoon

Analyst Ratings Changes

A number of equities analysts recently commented on ABBV shares. Cantor Fitzgerald decreased their price target on AbbVie from $250.00 to $240.00 and set an “overweight” rating for the company in a research note on Wednesday. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Guggenheim lifted their price target on AbbVie from $242.00 to $249.00 and gave the company a “buy” rating in a report on Friday. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $253.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.